NHS Digital Data Release Register - reformatted

Device Access UK Ltd

Project 1 — DARS-NIC-05429-H7X6R

Opt outs honoured: No - data flow is not identifiable (Does not include the flow of confidential data)

Sensitive: Non Sensitive

When: 2016/04 (or before) — 2020/10. breached contract with "high risk" — audit report.

Repeats: Ongoing, One-Off

Legal basis: Health and Social Care Act 2012, Health and Social Care Act 2012 – s261(1) and s261(2)(b)(ii)

Categories: Anonymised - ICO code compliant


  • Hospital Episode Statistics Admitted Patient Care
  • Hospital Episode Statistics Critical Care
  • Hospital Episode Statistics Outpatients
  • Hospital Episode Statistics Accident and Emergency
  • Emergency Care Data Set (ECDS)


Device Access Limited will use this data to conduct analysis to identify where within each local health economy medical technological devices can best be used by NHS providers in NHS patient care pathways to improve patient outcomes and to reduce lengths of stay, elective waiting times and diagnostic waiting times. Working through United Kingdom Trade and Investment (UKTI), the Office of Life Sciences (OLS) and the National Institute for Health Research (NIHR), National Institute for Health & Care Excellence (NICE), and working directly with Device Access’ medical technology clients, Device Access will carry out bespoke analysis of the data and provide that analysis to Device Access Limited clients. Such clients are medical technology companies that are or wish to become service providers to the NHS, or UK Government & NHS bodies (who receive services direct from Device Access). This will be in accordance with the UKTI and OLS government-linked priorities of supporting the wider UK health economy and is directly in line HSCIC’s key strategic aims/priorities as set out in “A strategy for the HSCIC 2013-2015

Yielded Benefits:

In 2018 Device Access have a number of new technologies going through NICE approvals; Treatments can be found on the following links NICE Interventional Procedures; https://www.nice.org.uk/guidance/indevelopment/gid-ipg10078 https://www.nice.org.uk/guidance/indevelopment/gid-ipg10061 MedTech Innovation Briefing (Pre-MedTech Guidance) The Vest (Device for airway clearance children with cystic fibrosis and neuromuscular disease) Rezum Steam Ablation for Benign Prostate Hyperplasia Cerebrotech VIPS (Stroke triage technology) to help identify patients with large vessel occlusion stroke for quicker transfer for treatment in the Regional NeuroScience Centres. Understanding NHS Heart Transplant outcomes and patient pathway activity helped us in 2014 to produce a paper to support NICE Approval with a company called Transmedics Inc who supply a new organ transplant system for the Heart. This was shown on a BBC2 documentary recently which highlighted the benefits of reducing the current 71% disposal of donated human hearts for transplantation. Link https://www.bbc.co.uk/programmes/b0b3gfth. We are now embarking on helping introduce the same platform for Lung & Liver transplantation

Expected Benefits:

Device Access Limited will continue working closely with the above named organisations, and supporting engagement with NICE medical technology evaluation programs. In the last year Device Access Limited held over 16 engagement meetings with NICE, including evaluation discussions on Dental, Neurology, Ophthalmology, ENT, Cardiac, Urology, Respiratory, Vascular, Imaging, Anaesthetics, Spinal, Orthopaedics, Rehabilitation, Maternity, Trauma and Oncology Medical Technologies. The analysis performed by Device Access Limited of HES data to examine historical, current and potential patient pathways has helped in these decision making processes. Device Access Limited has also been directly involved in supporting 6 formal NICE appraisals, some of which are currently under development. Patient pathway analysis is a critical part of these formal applications and appraisals, which result in the outputs of health economic and budget impact adoption models. Device Access Limited has a number of rolling contracts and we expect to produce outputs on these up until at least 2018. An example of the benefits derived from the data so far is the work carried out with regards to Donor Heart Transplantation. Research has shown that he majority of donated hearts are never used due to organ tissue deterioration during transportation between the donor site and recipient. Device Access Ltd have been supporting clients and clinicians by understanding the trends and outcomes between several NHS hospitals that uses a new technology which can preserve and diagnose the heart whilst being transferred from the donor to the recipient and comparing outcomes with those NHS hospitals that do not use this technology. During the extraction Device Access Ltd analysed the Admitted Patient Care data in conjunction with the critical care data to see lengths of stay (LOS) in critical care. By looking at the number of organs supported and period of time in critical care device access can demonstrate a reduction in LOS between hospitals that could be demonstrated for supporting a future NICE application. The HSCIC information was presented in April 2015 at the International Society for Heart and Lung Transplantation (ISHLT) in Nice, France. The technology is currently under review by NICE interventional procedures and Device Access havehas been providing our clients and clinicians supporting the review with the above data. Normothermic extracorporeal preservation of hearts for transplantation following donation after brainstem death http://www.nice.org.uk/guidance/indevelopment/gid-ip1289 The benefits of preserving more hearts for transplantation and ultimate transplant into recipients instead of the use of temporary artificial hearsthearts are widely recognised by the donor groups and NHS Blood and Transplant. This benefits the Health and Social Care agenda by both reducing cost of temporary devices such as left ventricular assist devices (LVADS) and also enabling thosesthose patients to have a great opportunity to have one heart transplant operation instead of multiple interventions. This technology featured on the BBC news: http://www.bbc.co.uk/news/health-32056350


The outputs will solely be aggregated analysis with small numbers suppressed. Such analysis will be only used :- - Within Applications to NICE for the purpose of Medical Technology Appraisal Program - To support NIHR research studies - To support UK Trade and Investment dialogue - To Support Office of Life Sciences (OLS) Dialogue - To support the adoption of medical technological devices with NHS providers - For internal decision making by medical device providers The data will not be used for any direct marketing purpose. Device Access Limited has a number of rolling contracts and we expect to produce outputs on these up until at least 2018. The objectives of these outputs or analysis are to improve patient care, pathways and healthcare outcomes.


The bespoke analysis Device Access Limited will provide to Device Access Limited clients will include only aggregated data with small numbers suppressed and at no point will record level data be supplied within UK or Worldwide. All analytical work will be carried out in line with HES Analysis Guide. Device Access Limited requires 4 64 historical years of HES data to support the overall patient pathway analysis. This will require the supply of outpatient, inpatient and critical care datasets. Device Access Ltd will need to keep historical data data for now up to 6 years. Sas for up to 6 years as some clients need to present a strong case to NICE for disease trends over a period of time. Device Access Limited does not hold any other patient record level datasets.